The use of these constructed uPAR/HER2-CAR-T cells resulted in smaller mean volumes of implanted tumors, together with reduced mean mass, a higher number of CAR copies in tumor tissues, a higher number of CD3+ cells, and a higher number of blood tumor cells compared with the conventional CAR-T cell treatment, as well as the uPAR-CAR-T cell and the HER2-CAR-T cell groups. This evidence concerns the gene PLAUR and neoplasm.